Neuronetics
Malvern, Pennsylvania, United States · Healthcare, Health Care
Key facts
- Headquarters
- Malvern, Pennsylvania, United States
- Employees
- 51
- Industries
- Healthcare, Health Care
- Status
- Public (STIM)
- Website
- neuronetics.com
- Company page
Recent activity at Neuronetics
- : SEC 8-K (1.01): On November 10, 2026, Neuronetics, Inc. entered into a Material Definitive Agreement by signing an Underwriting Agreement with William Blair & Company, L.L.C., whereby the Company agreed to issue and sell 18,750,000 shares of its common stock at a public price of $1.60 per share. The offering is expected to close on November 12, 2026, pending customary closing conditions. The estimated net proceeds from the offering will be approximately $27.7 million, which the Company plans to use to repay part of its outstanding term loans under a Credit Agreement with Perceptive Credit Holdings IV, LP, and for various corporate purposes including sales, marketing, and potential acquisitions. The Underwriters also have a 30-day option to purchase an additional 2,812,500 shares at the same price.
- : SEC 8-K (1.01): On November 5, 2026, Neuronetics, Inc. entered into Amendment No. 6 to its Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP. This amendment modifies certain revenue covenants and stipulates conditions for an optional prepayment of at least $15,000,000, among other terms. Notably, if these conditions are not satisfied by November 30, 2026, the amendment will automatically terminate, indicating its strategic importance to the company's financial management. This agreement follows a previous credit arrangement established on July 25, 2024, highlighting the ongoing financial relationship between Neuronetics and Perceptive.
- : SEC 8-K (7.01): On November 4, 2026, the Company released a presentation intended for certain investors, which outlines forward-looking statements regarding its business outlook for upcoming fiscal years. The presentation includes the Company’s expectations related to revenue, expenses, and growth, explicitly noting the potential impact of its transaction with Greenbrook TMS Inc. The filing contains a cautionary statement regarding risks and uncertainties that could affect these forward-looking statements. As it was released on the same day, it falls within the 3-day window for SEC disclosures.
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On August 11, 2026, Neuronetics issued a Regulation FD disclosure concerning a presentation intended for certain investors. The presentation, attached as Exhibit 99.2, includes forward-looking statements related to the company's business outlook, revenue expectations, and strategic plans for fiscal year 2026. Key risks and uncertainties highlighted include the impact of their transaction with Greenbrook TMS Inc. and other operational challenges that may affect their ability to achieve profitability. This disclosure aims to inform stakeholders while cautioning against overly relying on the forward-looking statements due to inherent business risks.
- : Neuronetics Inc. Appoints Nir Naor as Chief Financial Officer
- : SEC 8-K (5.02): On July 17, 2026, Neuronetics, Inc. and W. Andrew Macan entered into a Separation Agreement, marking Mr. Macan’s departure as Executive Vice President, Chief Legal Officer, and Corporate Secretary, effective August 15, 2026. Under the agreement, Mr. Macan will receive a retention bonus amounting to $231,750, along with 164,361 Restricted Stock Units that will vest on his Separation Date, and a Separation Payment totaling $475,087.50 over 12 months. His decision to leave was not due to any disputes with management or the Board. Additionally, the Board appointed Nir Naor as Executive Vice President, Chief Financial Officer, and Treasurer on July 9, 2026, effective around July 23, 2026, bringing over two decades of finance experience to the role.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On May 18, 2026, Neuronetics, Inc. amended and restated the consulting agreement with Francis X. Brown III, who serves as the Interim Principal Financial and Accounting Officer. This amendment clarifies that Mr. Brown will continue in his role until the Company hires a full-time replacement or unless otherwise agreed. The compensation for his services has been adjusted to $26,000 per month. This change is significant for the company's financial management as they transition towards stabilizing their executive team.
- : SEC 8-K (7.01): On May 5, 2026, Neuronetics released a presentation intended for potential investors, which is classified under Item 7.01 Regulation FD Disclosure. The presentation, attached as Exhibit 99.2, discusses the company's business outlook and expectations for the upcoming quarters and fiscal year 2026, including projections on revenue, expenses, and growth. The company emphasizes the uncertainties surrounding these forward-looking statements, which relate to the impact of recent transactions, including those with Greenbrook TMS Inc. The strategic implications highlight Neuronetics' reliance on their NeuroStar Advanced Therapy System for revenue generation, reflecting their ongoing focus on expanding market presence despite past operational challenges.
Neuronetics funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2023 | Debt Financing | $60.0M |
| Jun 2017 | Venture | $15.0M |
Leadership
- Christopher Thatcher, Executive Officer, Director
- Brian Farley, Director
- Stephen Campe, Director
- Wilfred Jaeger, Director
- Ron Hunt, Director
- Cory Anderson, Manager
- Nir Naor, Chief Financial Officer
- W. Andrew Macan, Secretary
- Steven E. Pfanstiel, Treasurer
- Steven Pfanstiel, Chief Financial Officer
- Sara Grubbs, Chief Revenue Officer
- Keith Sullivan, Chief Executive Officer
Verified email and direct lines for Neuronetics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Neuronetics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Neuronetics in the news
- Neuronetics: Top Line Growth, Low Valuation, But Gross Margin Struggles (NASDAQ:STIM) - Seeking Alpha (Jul 18, 2026)
- Malvern-based Neuronetics appoints new CEO, revenue surges after acquisition - The Business Journals (Mar 17, 2026)
- Neuronetics wins FDA clearance for device to treat adolescents with depression - MedTech Dive (Mar 27, 2024)
- Malvern’s Neuronetics Prices $30 Million Stock Offering, With Plans to Pay Down Debt - BioBuzz (Nov 11, 2026)
- FDA clears OCD cap from Neuronetics - MassDevice (Jun 12, 2023)
- Neuronetics goes public with $93.5M IPO following several VC rounds - Fierce Biotech (Jun 29, 2018)
- Neuronetics Announces Date for Second Quarter 2026 Financial and Operating Results Conference Call - Quiver Quantitative (Jul 28, 2026)
- Neuronetics Could Double, But The Balance Sheet May Crack First (NASDAQ:STIM) - Seeking Alpha (Jul 17, 2026)
Companies similar to Neuronetics
- iSpecimen · Healthcare, Health Care
- VitalConnect · Healthcare, Health Care
- Pharmazz · Healthcare, Health Care
- Modify Health · Healthcare, Health Care
- Osteal Therapeutics · Healthcare, Health Care
About Neuronetics: questions and answers
Where is Neuronetics headquartered?
Neuronetics is headquartered in Malvern, Pennsylvania, United States.
How many employees does Neuronetics have?
Neuronetics has about 51 employees.
Has Neuronetics raised funding?
Yes. Fundz has recorded 2 funding events for Neuronetics. The most recent, Debt Financing of $60.0M, was in Apr 2023.
Who leads Neuronetics?
Keith Sullivan is a Chief Executive Officer at Neuronetics.
What is the latest news on Neuronetics?
On Nov 12, 2026, SEC 8-K (1.01): On November 10, 2026, Neuronetics, Inc. entered into a Material Definitive Agreement by signing an Underwriting Agreement with William Blair & Company, L.L.C., whereby the Company agreed to issue and sell 18,750,000 shares of its common stock at a public price of $1.60 per share. The
Is Neuronetics a public company?
Yes. Neuronetics is publicly traded under the ticker STIM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy